Drug Trial Radar · NCT05146219
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Apr 2, 2022
Primary completion
Mar 21, 2024
Study completion Nov 13, 2024
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.
Conditions
- NSCLC
- EGFR Activating Mutation
- Brain Metastases
- Leptomeningeal Metastasis
Interventions
TY-9591 TabletsDrug
TY-9591 Tablets 160mg/d
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intracranial Overall Response Rate (iORR)Time frame: 13 months.
- Extracranial Overall Response Rate (eORR)Time frame: 13 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.